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Highlights: 
 
* The fixation of risèdronates on the bioactive glass surface has been highlighted.  
* Scanning electron microscopy shows the new morphology of this composite  
* Chemical analyses reveal the stability of adsorption process after 40 min of incubation. 
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Abstract: 
The aim of the current work is to study the physicochemical interactions between 
bisphosphonates molecules, risedronate (RIS) and bioactive glass (46S6) after their 
association by adsorption phenomenon. To more understand the interaction processes of RIS 
with the 46S6 surface we have used complementary physicochemical techniques such as 
Infrared (FTIR), RAMAN and nuclear magnetic resonance (NMR) spectroscopy. The 
obtained results suggest that risedronate adsorption corresponds to an ion substitution reaction 
with silicon ions occurring at the bioactive glass surface. Thus, a pure bioactive glass was 
synthesized and fully characterized comparing the solids after adsorption (46S6-XRIS 
obtained after the interaction of 46S6 and X% risedronate). Therefore, based on the 
spectroscopic results FTIR, RMAN and MAS-NMR, it can be concluded that strong 
interactions have been established between RIS ions and 46S6 surface. In fact, FTIR and 
RAMAN spectroscopy illustrate the fixation of risedronate on the bioactive glass surface by 
the appearance of several bands characterizing risedrontre. The 31P MAS-NMR  of the 
composite 46S6-XRIS show the presence of two species at a chemical shift of 15 and 19 ppm 
demonstrating thus the fixation of the RIS on 46S6 surface. 
Keywords: Adsorption, Bisphosphonate, bioactive glass, Risedronate, Spectroscopy. 
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1-Introduction: 
Bisphosphonate (BP) is a germinal (structurally similar) of pyrophosphate, a natural 
metabolite of bone. They contain a P-R1CR2-P backbone structure (cf. pyrophosphate P-O-
P), which allows a great number of possible variations, either by changing the two lateral 
chains on the carbons (R1 and R2) or by esterification of phosphate groups. They are used to 
treat different bone resorbing diseases, such as osteoporosis, tumor-associated osteolysis, and 
hyperparathyroidism [1-3]. Today, many different compounds of the bisphosphonate family 
are commercially available for the treatment of bone diseases. Each bisphosphonate has its 
own chemical, physicochemical and biological characteristics and vary thus greatly in 
efficacy [1]. Furthermore, derivatives with an amino group at the end of the side chain, the 
length of the side chain, and nitrogen containing ring structure increase further the activity by 
regulating the potency of bone resorption such as risedronate (RIS). 
Risedronate is a potent pyridinyl bisphosphonate currently licensed in the US for the 
treatment of Paget’s disease of bone and it is under development for the treatment and 
prevention of osteoporosis. It has been shown to be effective in the treatment of Paget’s bone 
disease [4, 5] and it improves or maintains bone mass for patients with postmenopausal and 
corticosteroid induced osteoporosis [6, 7]. 
The oral administration of bisphosphonate leads to several health diseases. Therefore, the 
regular administration of nitrogen-containing bisphosphonates causes gastrointestinal (GI) 
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adverse events for some patients [8, 9]. Indeed, the pyridinyl bisphosphonate risedronate has 
been shown to have a gastrointestinal safety profile similar to that of placebo [10, 11]. 
Currently, to prevent all complications of the oral administration of risedronate, experts 
discover other methods. Among them we mention implantlogy nevertheless these molecules 
can be implanted alone then it can be associated with other composites such as biomaterial. 
Biomaterial is a huge area, as it contains tricalcium phosphate, hydroxypatite [12, 13], 
calcium phosphate and bioactive glasses [14, 15].  
Bioactive glasses are a group of surface reactive glass- ceramic biomaterials and include 
original bioactive glass. This group of glasses was later termed “bioactive”, being “a material 
that elicits a specific biological response to the material surface which results in the formation 
of a bond between the tissues and the materials” [16, 17]. The adhesion of bioactive glass 
with other molecules involves several processes such as adsorption. There are several studies 
have been done on the adsorption of organic molecules (therapeutic agent) on apatite surface 
[18, 19] nevertheless, nearly no study has been interested in the association of therapeutic 
molecule with bioactive glass by adsorption phenomenon. For this reason, the aim of this 
work was to combine the therapeutic agents, as risedronates, in bioactive glass to synthesize a 
composite to be used as a bone graft. The incorporation of risedronate into bioactive glass to 
form bioactive glass/risedronate composite has been achieved using the adsorption process. 
This paper describes the elaboration of this hybrid material and the interactions between 
bioactive glass and risedronate. To achieve this, we adopted a global approach using 
complementary physicochemical techniques such as FTIR, RAMAN and Solid MAS- NMR 
spectroscopy in order to learn more about the interaction processes of risedronate with 
bioactive glass surface. 
 
2. Materials and methods 
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2.1. Synthesis of bioactive glass 
Bioactive glasses were synthesized by freeze-drying method. Chemical compositions of glass 
were 46 mass % SiO2 (silica), 24 mass % CaO (calcium oxide or lime), 24 mass % Na2O 
(Sodium oxide) and 6 mass % P2O5 (Phosphorus pentoxide). The premixed mixtures were 
melted in platinum crucibles to avoid the risk of contamination. The fusion temperature of 
platinum is of 1760°C for that it resists to these of the 46S6 (1300°C). The first rise of 
temperature rate was 10°C min-1 and was held at 900°C for 1 hour until the decarbonatation of 
all products. The second rise of temperature rate was 20°C/min and it was hold to 1300°C for 
3 hours. The samples were casted in preheated brass molds, in order to form cylinders of 13 
mm in diameter, and annealed at 565°C for 4 hours near the glass transition temperature. This 
glass was then ground using a milling machine, and sieved to obtain particles with a size 
distribution of 40 μm. 
 
2.2. Adsorption experiments 
Adsorption experiments were carried out at physiological temperature (37 ± 1 .C), by 
dispersing 50 mg of bioactive glass powder in 5 mL of risedronate solutions (concentration 
ranging from 0.8 to 2 mM) in a polyethylene tube. The latter were prepared by dissolving the 
appropriate amount of risedronate in an aqueous 1 mM KCl solution (standard solution); the 
pH of the obtained solutions was adjusted to 7.4 using hydrochloric acid and potassium 
hydroxide solutions. After sonication for 1–3 min, the suspensions were incubated for 20, 40, 
60 and 80 min without stirring and centrifuged for 20 min at 15000 rpm.  Two Blanks were 
used: the first contains only the risedronate prepared and incubated in the solutions 
corresponding to the adsorption tests but without bioglass while the second consists of the 
bioactive glass also prepared and incubated in the solution. After centrifugation, the obtained 
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solids were washed with deionised water and lyophilised. The supernatants were filtrated on 
millipore filters (0.2 μm). Thus we obtained three hybrid materials: 46S6-8RIS, 46S6- 12 RIS 
and 46S6- 20RIS. 
 
2.3. Solid phase characterization 
Several physicochemical methods were employed for the characterization of the prepared 
bioactive glass/ risedronate composite. Phase analysis was examined by X-ray diffraction 
(XRD) using a BRUKER AXS D8 ADVANCE diffractometer (λ = 1.54059 A°, Bragg–
Brentano geometry, 2Ɵ range of 10–70◦ for 20 min with a step size of 0.02). Infrared (FTIR) 
analyses were performed on ~ 1 mg of materials with metallic blade. Spectra were obtained 
between 4000 and 400 cm-1 wavenumber, with a resolution of 2cm-1. Raman spectra of the 
samples were generated on a Horiba, Jobin-Yvon Labram HR800 confocal 
microspectrometer, equipped with a helium–neon LASER (λ= 632.82 nm). The spectral 
resolution was 2 cm-1, the laser power was 2 mW and integration times varied from 30 to 120 
s. All spectra were recorded over a wavelength range of 200–1800 cm-1. Three spectral 
accumulations were averaged. Nuclear Magnetic Resonance (MASS) using Bruker MAS 
spectrometer ASX300 (7.05 T) was employed to highlight the microstructure of all 
compounds and finally Scanning Electron Microscopy (SEM) using Jeol JSM 6301F was 
used for the morphology investigations.  
 
2.4. Solution analysis 
The silicon content of the solutions obtained after adsorption experiment was measured by 
inductively coupled plasma-Optical Emission Spectrometry (ICP-OES) method. The 
risedronate concentration in the filtrates was determined using UV spectrophotometric 
absorption at 262 nm (Hewlett Packard 8452A Diode Array Spectrophotometer). This 
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wavelength corresponds to the maximum absorbance of the pyridine group. The calibration 
curve ranged from 0 to 0.43 mM. The molar absorption coefficient was approximately 3.9˟103 
at pH 7.4 [20]. 
The concentration of risedronates Cg (mM) in each point was calculated from the 
mathematical relation:  
 
Were:  
A: Absorbance, 
ɛ: Molar extinction coefficient (cm²/mol), 
l: Distance traveled by the light beam in the sample(cm), 
The relaxation time Ʈ of the system has been calcumated by the using the following 
mathematical relation: 
 
Were: 
Ʈ: relaxation time of the system 
Cg is the risedronate concentration in each point,  
C0 is the risedronate limit concentration,  
t the incubation time  
  
The relaxation time of the system has been calculated for RIS alone, 46S6-8RIS, 46S6- 12RIS 
and 46S6-20 RIS after 0, 20, 40, 60 and 80 min of incubation in the KCl solution. 
 
3. Results and discussion 
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3.1. Solid phase characterization 
3.1.1. Crystalline structures: X-Ray diffraction (XRD) 
In this current study we associated the pure bioactive glass and the 8 %, 12 % and 20 % 
risedronate. Therefore, the XRD diagram of 46S6 corresponds to an amorphous system. The 
diffraction halo is present between 20 and 40 (2 theta) with a center of 32 °. This halo is 
characteristic of diffusion phenomena in the amorphous material and the absence of long 
range order in the matrix of biocative glass [21] whereas risedronate crystallizes in a 
monoclinic system, presenting several lines [22]  (Figure 1) 
Different compositions based on different amount of risedronateds 46S6-XRIS (8, 12 and 
20%) have been studied. Therefore, after 80 min of their incubation revealed an amorphous 
structure. There was no additional crystalline solid phase observed after risedornate 
adsorption in the composite 46S6-XRIS (Figure 2). The same result was revealed after the 
association of tiludronate with nanocrystalline apatite [23] 
 This was due to the association method (adsorption) which is a surface phenomenon. 
Moreover adsorption is the adhesion of atoms, ions, or molecules from a dissolved solid to 
a surface.  It is a surface-based process [24]  
3.1.2. FTIR spectroscopy 
Infrared spectra of the bioactive glass (46S6), risedronate (RIS) and of composites 46S6-
XRIS are presented in Figures 3 and 4. For bioactive glass, the spectrum shows the 
characteristic bands of silica network. It reveals four broad absorption bands. First band about 
503 cm-1 is characteristic to angular deformation vibration of Si-O-Si band between SiO4 
tetrahedrons in silicate network. Three other characteristic bands at 745, 932 and 1036 cm-1 
attributed to stretching vibrations of Si-O band in each SiO4 tetrahedron are detected. In 
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addition, only slight band at 590 cm- 1 is characteristic for bending vibration of O-P-O group. 
It highlights the presence of a small amount of phosphate linked to the silica network [25-27]. 
The infrared spectrum of risedronate illustrates the presence of several bands, therefore we 
note the presence of C = O bands at 1700 cm -1 and 1130 cm -1. Also we remark the presence 
of C = N,  C = C and C-N = O bands respectively at 1200 cm-1 (amide), 1666 cm-1 and 1570 
cm-1 . Finally, we observe the presence of P-O band at 537 and 468 cm-1 [22]. The risedronate 
sodium salt showed two intense bands in the 1025–1055 cm-1 region assigned to C-H pyridine 
ring deformation, strongly impacted by hydrogen bonding between the pyridine ring and an 
adjacent phosphate group [28]. 
Infrared spectra of all composites 46S6-20RIS after 20 min, 40 min, 60 min and 80 min 
illustrate the presence of bands characterizing 46S6 and RIS. Thus, these composites reveal 
the presence of Si-O band at 503 cm-1 which was slightly shifted and decreased of intensity. 
Also we note the existence of two bands of C=O, the first at 1700 cm-1which was slightly 
shifted to the right and the second at 1130 cm-1 this was with a slight intensity. We remark 
also the presence of C = N,  C = C and of  C-N = O bands respectively at 1200 cm-1 (amide), 
1666 cm-1 and 1570 cm-1 . These were slightly shifted to the right. Finally, we notice the 
presence of P-O bands at 468 and 537 cm-1. This highlights the fixation of risedonate at the 
surface of bioactive glass and explains the chemical reactivity of our adsorbent. This result 
exhibits the good chemical reactivity of bioactive glass surface. It is in good agreement with 
others works [29, 21] 
 
3.1.3. RAMAN spectroscopy 
Raman spectra of the samples which contained bioactive glass has the characteristic broad 
bands at approximately 605 and 947 cm-1 corresponding to Si- O- Si rocking vibration, non-
bridging Si- O and Si- O- Si asymmetric stretching modes, respectively [30]. 
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Raman spectra of the combination between 8% RIS illustrates only Si-O characterizing 
bioactive glass. This result was explained by the low quantities of risedronate which have 
been associated with our bioactive glass. However, the Raman spectra of the association 
between bioactive glass and 20% of risedronate shows the presence of 4 bands characteristic 
of C-C at 249, 286, 401 and 418 cm-1. It corresponds to an association and chemical 
interaction between bioactive glass and risedronate. This result is in good agreement with 
other data reported by Barroug [22] during the association between nanocrystalline apatites 
and risedronate. Also this finding illustrates the interaction between bioactive glass and 
bisphosphonates, thus this result coincide with other studies [31]. Then, we remark the 
presence of C-P bands at 612 and 814 cm-1 and also the appearance of two bands of P-OH at 
849 and 872 cm-1. At the same time we observe the presence of the three bands of bioactive 
glass at the raman shifts respectively 347, 624 and 942 cm-1. These details clarify the 
association of risedronate with bioglass (Figure 5). 
 
3.1.4. NMR spectroscopy 
The 31P MAS-NMR spectrum obtained for the pure bioactive glass and the results of its 
decomposition, illustrates a chemical displacement which characterizes phosphorus in an 
orthophosphate environment PO43-. It corresponds to the Q0 species. 
The chemical displacement obtained for the pure bioactive glass is comprised between the 
chemical displacement of 31P of the Na3PO4 (10 and 16 ppm) and the 31P of Ca3 (PO4) (0 and 
3ppm), which clearly illustrates the absence of binding with these compounds [39]. 
 The 31P MAS - NMR spectrum obtained for the 46S6-8RIS and the results of its 
decomposition shows the presence of the compound Q0 with a proportion of 100% and with a 
chemical shift to 8 ppm whereas the 31P MAS- NMR spectrum obtained for the 46S6-12RIS 
and the results of its decomposition revealed the decreasing of Q0 to 93% and the appearance 
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of other compound QRIS1 (compound present in the 31P MAS-NMR spectra of risedronates) at 
a chemical displacement to 19 ppm and with a proportion of 7%. This result is in agreement 
with the other studies [32]  
The 31P MAS- NMR spectrum obtained for the 46S6-20RIS and the results of its 
decomposition show the presence of the compound Q0 with a proportion of 88%, the 
increasing of the compound QRIS1 to 8% with a chemical shift at 19 ppm, we note also the 
appearance of other species QRIS2 (compound also present in the 31P MAS-NMR spectra of 
risedronates) with a chemical displacement to 15 ppm and with a proportion of 4%. These 
data illustrate the fixation of risedronate to bioactive glass which revealed by the appearance 
of compounds characterizing risedonate in the spectratum of 46S6-12RIS and 46S6-20RIS 
(Figure 6 and Table 1). 
The same result is reported by RAMAN spectroscopy. Then, after the association of 8% 
risedronates with bioactive glass, there are no additional band to 46S6 Raman spectratum and 
no new compound in 31P MAS-NMR are revealed whereas after the association of 12% and 
20% risedronate we note the appearance of new bands characterizing risedronate in the 
RAMAN spectratum and the appearance of new compounds in 31P MAS-NMR corresponding 
to risedronates species. These findings could be explained by the few quantity of risedronate 
added to 46S6 material in the composite 46S6-8 RIS.   
 Findings reported by 46S6-12 RIS and 46S6-20 RIS are in conformity with the results 
reported by Barroug [22], after the association of risedronate to the nanocrystalline apatites 
and which proved by the appearance of risedronate compounds in the spectratum of the 
composite risedronate –naocrystalline apatites. 
 
3.1.5. Morphological study by scanning electron microscopy (SEM) coupled with 
energy-dispersive X-ray: 
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The obtained results are shown in Figure 7A, 7B and 7C. The surface of 46S6 displays 
smooth fragments while the composite 46S6- XRIS exhibit rough surface. The risedronate 
crystals on the surfaces of composite are well observed. They adhered to the bioactive glass 
particles and created some interstices on the surface of the 46S6-XRIS composite. The 
risedronate molecules modify strongly the surface morphology of pure bioactive glass. They 
are found almost everywhere on the surface of the 46S6-XRIS composite due to their 
chemical affinity for calcium ions in the matrix of bioactive glass. Therefore, the combination 
of 8% and 12% of RIS with 46S6 shows the presence of the filaments coming encompass the 
bioactive glass blocks whereas after the association of 20% RIS with 46S6, the bioactive glass 
blocs is nearly encompassed by risedronate filaments. The same result is seemed after the 
association of risedronate with the nanocrystalline- apatite [22] and after the association of 
zoledronate with bioactive glass [33]. Thus, all these input illustrate the reactivity and the 
good chemical binding and interaction with other molecules of pure bioactive glass. 
Result reported by energy-dispersive X-ray showed the decreasing of Si quantities in the 
46S6-XRIS surface with the increasing of risèdronates associated with 46S6. Thus, this result 
highlights the SEM data.  Therefore, the Si quantity decreased from 6.6 in 46S6-8RIS to 1.8 
in 46S6-20RIS. This results illustrates that 46S6-20RIS surface is nearly covered by 
risèdronates (Figure 8: A,B, C).  
 
3.2. Analysis of the solutions after uptake of risedronates (solution obtained after the 
filtration) 
Analyses of the obtained solutions after uptake of rideronate divulged that the binding of 
risedronate ions to the bioactive glass surface affected the amount of silicon ion in the 
solution. The evolution of this ion in solution as a function of risedronate adsorbed onto 46S6 
surface in Figure 9. The release of silicon ion increased upon uptake of risedronate. The 
Page 13 of 39
Ac
ce
pte
d M
an
us
cri
pt
13 
 
content of silicon ions in solution for the 46S6-20 RIS was significantly higher due to the 
specific solubility behavior of this type of biomaterial and the high quantity of risedronates 
which fixed in the silicon sites. These observations suggest that risedronate molecules 
substituted for silicon ions on the 46S6 surface. Several studies illustrate that the fixation of 
BP is accompanied by the release of some elements from the adsorbent surface such as the 
liberation of silicon and phosphorus. As reported by several authors [34, 35] for other BP, it 
can be postulated that risedronate species participate in an ionic exchange process with active 
mineral ions on the surfaces of bioactive glass, particularly silicon, which share the same 
ionic sites at the surface. Silicon intervenes in several physicochemical properties after its 
immersion in the SBF solution or after its in vivo experiment.  Consequently, the rate of bone 
formation at a bioactive glass implant interface can be altered by changing the glass 
composition [36, 37]. However, the release of phosphorus decreased with time incubation, 
this attenuation is explained by the reduction of risedronate phosphorus in the solution. Thus, 
this explained by the decreasing of phosphorus in the solution in favor of the increasing of 
risedronates fixation in the 46S6 surface (Figure 10) 
The binding of risedronate with bioactive glass was evaluated by using UV 
spectrophotometric absorption at a pH= 7.4, temperature = 25 and at a wavenumber λ = 362 
nm. This wave number is chieved from the calibration of the solution with 2 mM of 
risedronate (Figure 11).   
The kinetic release of risedronates in KCl during the association of risedronate with bioactive 
glass was studied by UV visible. Therefore, we note that the release of this molecule reaches 
its threshold for compounds 46S6-8RIS, 46S6-12RIS and 46S6-20RIS after 40 min of 
incubation. This result illustrates the maximum attachment of risedronates on 46S6 after 40 
min and exhibits the fixation of RIS on the 46S6 surface with a speedy kinetic (Figure 12). 
Others similar results were reported by the literature of the interaction of apatite with different 
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bisphosphonates [38], with the adenosine 5- monophosphate [39] and with phosphocitrates 
[40]. This finding explains the high reactivity of the 46S6 surface to the molecules of 
biological interest. Additionally, this result explains that resedronate presents an early release 
due to its hydrophilic character, the same results is reported in previous works after the 
immersion of gentamicin sulfate in the PBS solution [41]. 
Ʈ min of 46S6- 8RIS, 46S6-12RIS and 46S6-20 RIS system relaxation respectively after 0 
min, 20 min, 40 min, 60 min and 80 min for each composite increased between 20 min and 40 
min then they were stabilized. This data discloses that risedronates achieve its threshold of 
release after 40 min (Figure 13).   
The comparison of Δ (Ʈ min) of all composites 46S6-8RIS, 46S6-12 RIS and 46S6-20 RIS 
reveals its increasing with the rise of risedronates quantity added to 46S6.  
 
4-Conclusion: 
This study suggests that risedronate adsorption on bioglass supports corresponds to an ion 
substitution reaction with silicon ions at the crystal surface. This mechanism explains the 
reactivity of 46S6 surface. Moreover, the association between 46S6 and risedronate is showed 
by the appearance of bands characterizing 46S6 and risedronate in the composites 46S6-8RIS, 
46S6- 12RIS and 46S6-20RIS after its characterization by FTIR and RAMAN spectroscopy. 
This association is confirmed also by MAS-NMR 31P therefore we show the presence of 
species characterizing RIS in the composites BG-12RIS and BG-20RIS.  Bioactive glass/ 
risedronate association   was demonstrated also by using of SEM micrograph and XRD 
diffraction but most clearly with Raman, FTIR and MAS-NMR. Chemical analyses illustrate 
that the fixation and the release of risedronates achieved its maximum after 40 min of 
incubation. The combination of FTIR, Raman, solid NMR spectroscopy and chemical 
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analyses proved to be a powerful multidisciplinary approach to understand the interaction 
between bioglass and bisphosphonate molecules. 
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Figures captions 
Figure 1: X-ray diffraction of 46S6 and risedronates   
Figure 2: X-ray diffraction of 46S6-20 RIS after different incubation times (20, 40, 60 and 80 
min) in the KCl solution,  
Ris: risedronate 
Figure 3: FTIR Spectra of 46S6 and Risedronate, 
Figure 4: FTIR spectra of 46S6-20 RIS after different incubation times (20, 40, 60 and 80 
min) in the KCl solution,  
Ris: risedronate 
Figure 5: RAMAN Spectra of 46S6, pure risedronate, 46S6-8RIS and 46S6-20 RIS after 
incubation in the KCl solution, 
Ris: risedronates 
Figure 6: MAS-NMR 31P of 46S6, 46S6-8RIS, 46S6-12 RIS and 46S6-20 RIS after their 
incubation in the KCl solution, 
Ris: risedronates 
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Figure 7: SEM images of 46S6-8 RIS (A), 46S6-12 RIS (B) and 46S6-20 RIS (C) after its 
incubation in the KCl solution, 
Ris: risedronates 
Figure 8: EDS of 46S6-8RIS, 46S6-12RIS and 46S6-20RIS after 40 of incubation in the KCl 
solution. 
Ris: risedronates 
Figure 9: Kinetic release of silicon from 46S6, 46S6-8RIS, 46S6-12RIS and 46S6-20RIS 
after different incubation times (20, 40, 60 and 80 min) in the KCl solution, 
Ris: risedronates 
 
Figure 10: Kinetic release of Risedronates from 46S6, 46S6-8RIS, 46S6-12RIS and 46S6-
20RIS after different incubation times (20, 40, 60 and 80 min) in the KCl solution, 
Ris: risedronates 
Figure 11: UV-Visible spectrum of risedronate sodium (0.2mM) in KCl solution 1mM at 
pH=7.4 and at 25°C, 
Ris: risedronates 
Figure 12: UV-Visible spectrum of kinetic risedronate release from pure risedronate, 46S6-
8RIS, 46S6-12RIS and 46S6-20RIS after different incubation times (20, 40, 60 and 80 min) in 
the KCl solution. 
Ris: risedronates 
Figure 13: Relaxation time (Ʈ) of 46S6-XRIS (X=8, 12 and 20 min) after 0, 20, 40, 60 and 80 
of incubation in the KCl solution. 
Ris: risedronates 
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Table caption 
Table 1: Contribution and chemical shifts of different species in 31P spectra of bioactive pure 
glass (46S6) and composites 46S6-XRIS (X= 8, 12 and 20).  
 
Composites 
 
                                             Compounds 
  
Q0 
 
QRIS1 
 
QRIS2 
 
ppm 
 
% 
 
ppm 
 
% 
 
ppm 
 
% 
 
46S6 
 
7 
 
100 
 
0 
 
0 
 
0 
 
0 
 
46S6-8RIS 
 
8 
 
100 
 
0 
 
 
0 
 
0 
 
0 
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46S6-12RIS 
 
8 
 
93 
 
19 
 
7 
 
0 
 
0 
 
46S6-20RIS 
 
8 
 
88 
 
19 
 
 
8 
 
15 
 
4 
 
 
 
 
P
ag
e 
25
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 1
P
ag
e 
26
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 2
P
ag
e 
27
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 3
P
ag
e 
28
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 4
Page 29 of 39
Ac
ce
pte
d M
an
us
cri
pt
Figure 5
Page 30 of 39
Ac
ce
pte
d M
an
us
cri
pt
Figure 6
Page 31 of 39
Ac
ce
pte
d M
an
us
cri
pt
Figure 7A
P
ag
e 
32
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 7
B
P
ag
e 
33
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 7
C
P
ag
e 
34
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 8
P
ag
e 
35
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 9
P
ag
e 
36
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 1
0
P
ag
e 
37
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 1
1
P
ag
e 
38
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 1
2
P
ag
e 
39
 o
f 3
9
Ac
ce
pte
d M
an
us
cri
p
Fi
gu
re
 1
3
